article
Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No 1925/2006 in the European Union (EU). Once executed, this could lead to a ban of the use as an ingredient in food supplements. In this review authors assess efficacy evidence stemming from 133 clinical trials conducted over a period of 45 years for what are the best-documented efficacy endpoints.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.22541/au.177507189.90771178/v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
